1-2 of 2
Mindaugas Jurgutis, MD
Close
Sort by
Journal Articles

Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)

Animesh Pardanani, MBBS, PhD, Claire N Harrison, DM, FRCP, FRCPath, Jorge E. Cortes, MD, Francisco Cervantes, MD, Ruben A. Mesa, MD, Donald Milligan, MD, FRCP, FRCPath, Tamás Masszi, MD, PhD, Elena Mishchenko, MD, Eric Jourdan, MD PhD, Alessandro M. Vannucchi, MD, Mark Drummond, MD PhD, Mindaugas Jurgutis, MD, Kazimierz Kuliczkowski, Emanuil Gheorghita, MD, Francesco Passamonti, MD, Frank Neumann, Guozhi Gao, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2013) 122 (21): 393.
https://doi.org/10.1182/blood.V122.21.393.393
Published: 2013
Journal Articles

Symptom Burden and Health-Related Quality Of Life (HRQoL) In Patients With Myelofibrosis (MF) Treated With Fedratinib (SAR302503) In a Phase III Study (JAKARTA)

Ruben A. Mesa, MD, Jorge E. Cortes, MD, Francisco Cervantes, MD, Donald Milligan, MD, FRCP, FRCPath, Tamás Masszi, MD, PhD, Elena Mishchenko, MD, Eric Jourdan, MD PhD, Alessandro M. Vannucchi, MD, Mark Drummond, MD PhD, Mindaugas Jurgutis, MD, Kazimierz Kuliczkowski, Professor, Emanuil Gheorghita, MD, Francesco Passamonti, MD, Frank Neumann, Florence Joulain, MSc, Sheikh Usman Iqbal, MD MPH MBA, Claire N Harrison, DM, FRCP, FRCPath
Journal: Blood
Blood (2013) 122 (21): 4061.
https://doi.org/10.1182/blood.V122.21.4061.4061
Published: 2013